Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLXNASDAQ:AVDLNASDAQ:SWTXNASDAQ:ZLAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$63.57-0.2%$61.46$47.86▼$107.37$3.51B0.34604,003 shs803,679 shsAVDLAvadel Pharmaceuticals$9.13-1.0%$8.36$6.38▼$17.30$883.23M1.41.24 million shs1.46 million shsSWTXSpringWorks Therapeutics$46.72+0.1%$43.28$28.21▼$62.00$3.52B0.772.23 million shs4.43 million shsZLABZai Lab$30.29-3.3%$31.08$16.01▼$39.77$3.34B1.04868,280 shs626,776 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx0.00%-0.55%-2.99%-1.93%+26.01%AVDLAvadel Pharmaceuticals0.00%0.00%+6.04%+15.42%-41.44%SWTXSpringWorks Therapeutics0.00%+0.52%+1.10%-19.11%+14.34%ZLABZai Lab0.00%-3.29%-2.76%-12.56%+68.65%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACLXArcellx2.249 of 5 stars3.51.00.00.03.82.50.0AVDLAvadel Pharmaceuticals2.2396 of 5 stars3.51.00.00.03.41.70.6SWTXSpringWorks Therapeutics1.7781 of 5 stars3.12.00.00.02.90.80.6ZLABZai Lab2.7084 of 5 stars3.43.00.00.03.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 3.07Buy$111.3375.14% UpsideAVDLAvadel Pharmaceuticals 3.00Buy$19.43112.80% UpsideSWTXSpringWorks Therapeutics 2.13Hold$52.5712.52% UpsideZLABZai Lab 2.75Moderate Buy$47.3756.38% UpsideCurrent Analyst Ratings BreakdownLatest AVDL, ACLX, SWTX, and ZLAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025SWTXSpringWorks TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$47.00 ➝ $47.005/9/2025ACLXArcellxScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$133.00 ➝ $93.005/8/2025AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.004/30/2025SWTXSpringWorks TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$74.00 ➝ $47.004/29/2025SWTXSpringWorks TherapeuticsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold4/29/2025SWTXSpringWorks TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$66.00 ➝ $47.004/28/2025SWTXSpringWorks TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$77.00 ➝ $47.004/28/2025SWTXSpringWorks TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/28/2025SWTXSpringWorks TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$63.00 ➝ $47.004/28/2025SWTXSpringWorks TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$81.00 ➝ $47.004/9/2025AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$76.81M45.61N/AN/A$9.97 per share6.38AVDLAvadel Pharmaceuticals$194.45M4.54N/AN/A$0.98 per share9.32SWTXSpringWorks Therapeutics$219.67M16.03N/AN/A$10.01 per share4.67ZLABZai Lab$418.33M7.99N/AN/A$8.05 per share3.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$70.69M-$2.99N/AN/AN/A-25.94%-8.28%-5.21%8/14/2025 (Estimated)AVDLAvadel Pharmaceuticals-$160.28M-$0.27N/A152.17N/A-52.53%-93.34%-44.77%8/14/2025 (Estimated)SWTXSpringWorks Therapeutics-$325.10M-$3.41N/AN/AN/A-134.73%-46.74%-41.12%8/6/2025 (Estimated)ZLABZai Lab-$334.62M-$2.49N/AN/AN/A-76.14%-36.97%-27.10%8/5/2025 (Estimated)Latest AVDL, ACLX, SWTX, and ZLAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025SWTXSpringWorks Therapeutics-$0.81-$1.11-$0.30-$1.11$64.19 million$49.09 million5/8/2025Q1 2025ACLXArcellx-$0.84-$1.13-$0.29-$1.13$19.51 million$8.13 million5/8/2025Q1 2025ZLABZai Lab-$0.50-$0.45+$0.05-$0.45$118.40 million$106.49 million5/7/2025Q1 2025AVDLAvadel Pharmaceuticals-$0.07-$0.05+$0.02-$0.05$50.57 million$52.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ASWTXSpringWorks TherapeuticsN/AN/AN/AN/AN/AZLABZai LabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.294.29AVDLAvadel PharmaceuticalsN/A2.972.60SWTXSpringWorks TherapeuticsN/A6.166.02ZLABZai LabN/A3.012.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%AVDLAvadel Pharmaceuticals69.19%SWTXSpringWorks TherapeuticsN/AZLABZai Lab41.65%Insider OwnershipCompanyInsider OwnershipACLXArcellx8.35%AVDLAvadel Pharmaceuticals4.80%SWTXSpringWorks Therapeutics7.83%ZLABZai Lab4.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.11 million50.70 millionOptionableAVDLAvadel Pharmaceuticals7096.74 million91.74 millionOptionableSWTXSpringWorks Therapeutics23075.35 million68.73 millionOptionableZLABZai Lab1,950110.33 million94.24 millionOptionableAVDL, ACLX, SWTX, and ZLAB HeadlinesRecent News About These CompaniesMillennium Management LLC Sells 15,023 Shares of Zai Lab Limited (NASDAQ:ZLAB)June 1 at 3:44 AM | marketbeat.comZai Lab Limited (NASDAQ:ZLAB) Sees Large Drop in Short InterestJune 1 at 2:43 AM | marketbeat.comZai Lab Limited (ZLAB) & NovoCure Limited (NVCR)’s TTFields Therapy Succeeds in Phase 3 TrialMay 31 at 8:48 PM | insidermonkey.comZai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual MeetingMay 31 at 3:08 PM | businesswire.comZai Lab Announces Participation in Investor Conferences in June 2025May 30 at 7:30 AM | businesswire.comNorthern Trust Corp Increases Holdings in Zai Lab Limited (NASDAQ:ZLAB)May 29 at 3:08 AM | marketbeat.comZai Lab Limited Is Well Positioned For Long-Term GrowthMay 28, 2025 | seekingalpha.comZai Lab Limited Is Well Positioned For Long-Term GrowthMay 28, 2025 | seekingalpha.comBNP Paribas Financial Markets Purchases 18,472 Shares of Zai Lab Limited (NASDAQ:ZLAB)May 26, 2025 | marketbeat.comTwinbeech Capital LP Buys Shares of 27,039 Zai Lab Limited (NASDAQ:ZLAB)May 24, 2025 | marketbeat.comZai Lab Limited: Banking On Chinese Pharma GrowthMay 22, 2025 | seekingalpha.comWoodline Partners LP Has $46.09 Million Stock Holdings in Zai Lab Limited (NASDAQ:ZLAB)May 22, 2025 | marketbeat.comPoint72 Asset Management L.P. Purchases 270,136 Shares of Zai Lab Limited (NASDAQ:ZLAB)May 22, 2025 | marketbeat.com43,178 Shares in Zai Lab Limited (NASDAQ:ZLAB) Acquired by Lazard Asset Management LLCMay 22, 2025 | marketbeat.comVestal Point Capital LP Invests $7.86 Million in Zai Lab Limited (NASDAQ:ZLAB)May 21, 2025 | marketbeat.comZai Lab gets FDA fast track status for lung cancer treatmentMay 19, 2025 | msn.comRTW Investments LP Takes Position in Zai Lab Limited (NASDAQ:ZLAB)May 18, 2025 | marketbeat.comBalyasny Asset Management L.P. Sells 233,103 Shares of Zai Lab Limited (NASDAQ:ZLAB)May 18, 2025 | marketbeat.comLMR Partners LLP Makes New Investment in Zai Lab Limited (NASDAQ:ZLAB)May 17, 2025 | marketbeat.comMPM Bioimpact LLC Purchases Shares of 800,000 Zai Lab Limited (NASDAQ:ZLAB)May 16, 2025 | marketbeat.comYing Du Sells 46,389 Shares of Zai Lab Limited (NASDAQ:ZLAB) StockMay 16, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVDL, ACLX, SWTX, and ZLAB Company DescriptionsArcellx NASDAQ:ACLX$63.57 -0.11 (-0.17%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$62.00 -1.57 (-2.47%) As of 05/30/2025 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Avadel Pharmaceuticals NASDAQ:AVDL$9.13 -0.09 (-0.98%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$9.08 -0.05 (-0.59%) As of 05/30/2025 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.SpringWorks Therapeutics NASDAQ:SWTX$46.72 +0.04 (+0.09%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$46.62 -0.09 (-0.20%) As of 05/30/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.Zai Lab NASDAQ:ZLAB$30.29 -1.02 (-3.26%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$30.14 -0.15 (-0.50%) As of 05/30/2025 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
